Clinical Trial Update: Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP) [Phase 2]

View source ↗

Summary

The BLOCK-ROP Phase 2 trial evaluating pan-VEGF blockade for retinopathy of prematurity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Pan-VEGF blockade (pan-VEGF inhibitor)

Snippet

Sponsor: Vision Research Foundation | Conditions: Retinopathy of Prematurity | Phase 2 | Status: WITHDRAWN